Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May 3;2(5):luae065.
doi: 10.1210/jcemcr/luae065. eCollection 2024 May.

The Role of Imatinib in Pediatric Type 1 Diabetes

Kristen Lavelle  1   2   3 , Chester Chamberlain  2   3 , Michael German  1   2   3 , Mark Anderson  1   3 , Angel Nip  4 , Stephen E Gitelman  3   4
Affiliations
Case Reports

The Role of Imatinib in Pediatric Type 1 Diabetes

Kristen Lavelle et al. JCEM Case Rep. .

Abstract

We report the first case of imatinib use in an adolescent with diabetes and suggest that it impacts the natural course of disease. A 14-year-old male patient presented in diabetic ketoacidosis (DKA) and was diagnosed with presumed autoantibody-negative type 1 diabetes (T1D) as well as myeloid neoplasm with platelet-derived growth factor receptor beta (PDGFRB) rearrangement. After starting exogenous insulin and imatinib, he experienced a 1.7-point reduction in glycated hemoglobin (HbA1c) and a 71% reduction in insulin requirement with sustained partial diabetes remission. Our case suggests imatinib as a potential therapeutic agent for pediatric T1D.

Keywords: case report; diabetes; imatinib; pediatric.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
2-week Dexcom G6 CGM/OmniPod 5 download with daily trends from approximately 15 months post-diagnosis and 12 months after starting imatinib.
Figure 2.
Figure 2.
A) HbA1c over time in months since diabetes diagnosis with imatinib initiation indicated by arrow. B) Insulin use in units/kilogram/day over time in months since diabetes diagnosis with imatinib initiation indicated by arrow. C) Weight percentile over time in months since diabetes diagnosis with imatinib initiation indicated by arrow.
See this image and copyright information in PMC

References

    1. Hägerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 2007;21(2):618‐628. - PubMed
    1. Morita S, Villalta SA, Feldman HC, et al. Targeting ABL-IRE1α signaling spares ER-stressed pancreatic β cells to reverse autoimmune diabetes. Cell Metab. 2017;25(4):883‐897.e8. - PMC - PubMed
    1. Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008;105(48):18895‐18900. - PMC - PubMed
    1. Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26(11):643‐656. - PubMed
    1. Gitelman SE, Bundy BN, Ferrannini E, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(8):502‐514. - PMC - PubMed

Publication types